MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference
February 14 2018 - 4:30PM
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical
company pioneering a precision medicine approach for the treatment
of heritable cardiovascular diseases, today
announced that senior management will participate in a
fireside chat at the RBC Capital Markets’ 2018 Healthcare
Conference on Wednesday, February 21, 2018, at 8:30 a.m. ET in New
York, NY.
A webcast of the presentation will be available
by visiting the Investors section of MyoKardia’s website
at http://investors.myokardia.com. A replay of the webcast
will be available on the MyoKardia website for 90 days
following the conference.
About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company
pioneering a precision medicine approach to discover, develop and
commercialize targeted therapies for the treatment of serious and
rare cardiovascular diseases. MyoKardia’s initial focus is on
the treatment of heritable cardiomyopathies, a group of rare,
genetically-driven forms of heart failure that result from
biomechanical defects in cardiac muscle
contraction. MyoKardia has used its precision
medicine platform to generate a pipeline of therapeutic programs
for the chronic treatment of the two most prevalent forms of
heritable cardiomyopathy – hypertrophic cardiomyopathy (HCM) and
dilated cardiomyopathy (DCM). MyoKardia’s most advanced
product candidate is mavacamten (MYK-461), a novel, oral,
allosteric modulator of cardiac myosin that has been shown to
reduce hypercontractility in early clinical studies and is
currently being studied in the Phase 2 PIONEER-HCM clinical
trial. MYK-491, MyoKardia’s second product candidate, is
designed to increase the overall extent of the heart’s contraction
in DCM patients by increasing cardiac contractility.
MyoKardia is currently evaluating MYK-491 in a Phase 1b study
in DCM patients. A cornerstone of
the MyoKardia platform is the Sarcomeric Human
Cardiomyopathy Registry (SHaRe), a multi-center, international
repository of clinical and laboratory data on individuals and
families with genetic heart disease,
which MyoKardia helped form in 2014. MyoKardia’s
mission is to change the world for patients with serious
cardiovascular disease through bold and innovative science.
Contacts
Beth DelGiacco (Investors)Stern Investor Relations, Inc.
212-362-1200 beth@sternir.com
Steven Cooper (Media)Edelman 415-486-3264
steven.cooper@edelman.com
MyoKardia (NASDAQ:MYOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
MyoKardia (NASDAQ:MYOK)
Historical Stock Chart
From Apr 2023 to Apr 2024